|
|
 |
|
  |
|
News Center
January 28, 2013 AGY Therapeutics to Present at International viagra générique Conference.
February 02, 2005 AGY Therapeutics to Present at International Stroke Conference. >>
July 20, 2004 AGY Therapeutics Licenses Product Candidate from M's Science for Phase 2 Clinical Development. >>
April 29, 2004 AGY Therapeutics Relocates to New Facilities in South San Francisco. >>
April 04, 2004 AGY Therapeutics Raises Total of $9 Million in Extension of C Round Financing. >>
February 10, 2004 AGY Therapeutics Identifies Cathepsin B as Important in Mediating Nerve Cell Death in Cellular Model of Alzheimers Disease. >>
February 03, 2004 AGY Therapeutics Appoints Timothy McBride as Senior Vice President of Business Development. >>

October 03, 2003 AGY Therapeutics Identifies Novel Therapeutic Target for Aggressive Form of Brain Cancer Findings Published in the Peer-Reviewed Journal Oncogene. >>
September 15, 2003 AGY Therapeutics Presents Data on Novel Targets and Compounds for Stroke Therapy at International Conference. >>
July 17, 2003 AGY Therapeutics' Scientists Identify Novel Protein that Limits Damage Induced by Stroke to Nerve Cells. >>
April 2, 2003 AGY Therapeutics Selected to Present at Future Leaders in Biotech Industry Conference. >>
January 7, 2003
AGY Therapeutics to Present at JP Morgan H&Q Healthcare Conference. >>

November 22, 2002
AGY Identifies and Patents Promising Drug Targets for Most Common and Deadly Brain Tumors. >>
November 6, 2002
AGY Therapeutics Presents at Annual Society for Neuroscience Meeting. >>
July 10, 2002
AGY Therapeutics Raises $31.3 Million and Appoints Two New Board Members. >>
April 26, 2002
AGY Therapeutics' CEO, Karoly Nikolich, is Featured in the April 2002 Edition of the Bio Business Review. >>
April 24, 2002
AGY Therapeutics Advances Novel Proprietary Stroke Targets Into Drug Discovery Programs. >>
April 17, 2002
AGY Therapeutics Starts Drug Discovery Program Based on Novel Proprietary Alzheimer's Disease Target. >>
January 17, 2002
Curis and AGY Therapeutics Announce Collaboration to Discover Small Molecule Drugs for CNS, Oncology, Neurodegenerative Diseases, and Diabetes. >>
January 3, 2002
AGY Therapeutics to Present at J.P. Morgan H&Q Healthcare Conference. >>

November 15, 2001
AGY Therapeutics Identifies Protective and Destructive Genes for Stroke That May Lead to Novel Therapies. >>
November 15, 2001
AGY Therapeutics Announces Study Demonstrating Utility of RNA Interference in Mammalian Cells for CNS Drug Discovery. >>
October 31, 2001
AGY Therapeutics Establishes Scientific Advisory Board of Neuroscience Leaders. >>
September 5, 2001
AGY Therapeutics Announces Appointment of Roman Urfer, Ph.D. as Vice President of Drug Discovery and Development. >>
June 28, 2001
AGY Therapeutics Signs Agreements to Identify Drug Targets in Central Nervous System Diseases and Obesity. >>
May 7, 2001
AGY Therapeutics Raises $13 Million. >>
April 25, 2001
AGY Therapeutics Presents at IBC Target Validation Meeting. >>
January 8, 2001
AGY Therapeutics Presents at Chase Hambrecht & Quist 19th Annual Healthcare Conference. >>

November 6, 2000
AGY Therapeutics Identifies Genes Providing Neuroprotective Effects Following Stroke. >>
|
|